Kennedy Capital Management LLC Increases Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Kennedy Capital Management LLC increased its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 433.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 27,711 shares of the company's stock after purchasing an additional 22,517 shares during the period. Kennedy Capital Management LLC owned approximately 0.10% of Krystal Biotech worth $4,341,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in KRYS. Entropy Technologies LP acquired a new stake in shares of Krystal Biotech during the fourth quarter worth $548,000. Janney Montgomery Scott LLC raised its stake in Krystal Biotech by 42.0% in the 4th quarter. Janney Montgomery Scott LLC now owns 52,592 shares of the company's stock worth $8,239,000 after purchasing an additional 15,545 shares in the last quarter. Principal Financial Group Inc. raised its stake in Krystal Biotech by 3.1% in the 4th quarter. Principal Financial Group Inc. now owns 123,453 shares of the company's stock worth $19,340,000 after purchasing an additional 3,727 shares in the last quarter. abrdn plc boosted its holdings in Krystal Biotech by 32.5% in the 4th quarter. abrdn plc now owns 57,033 shares of the company's stock valued at $8,935,000 after purchasing an additional 13,979 shares during the period. Finally, Blue Trust Inc. grew its position in shares of Krystal Biotech by 74.4% during the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company's stock worth $159,000 after purchasing an additional 433 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Stock Up 2.3 %

Shares of NASDAQ KRYS traded up $3.87 during midday trading on Friday, reaching $168.57. 303,757 shares of the company were exchanged, compared to its average volume of 296,211. The stock has a market cap of $4.87 billion, a P/E ratio of 56.38 and a beta of 0.75. Krystal Biotech, Inc. has a one year low of $141.72 and a one year high of $219.34. The stock's 50-day moving average price is $174.73 and its 200-day moving average price is $171.98.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.29 by $0.23. The firm had revenue of $91.10 million during the quarter, compared to analysts' expectations of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company's revenue was up 116.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.30 EPS. On average, equities research analysts anticipate that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Cantor Fitzgerald reiterated an "overweight" rating and issued a $215.00 price target on shares of Krystal Biotech in a research note on Thursday, February 20th. Citigroup increased their target price on Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a report on Thursday, February 20th. Jefferies Financial Group assumed coverage on Krystal Biotech in a research note on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price target for the company. Chardan Capital increased their price objective on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a research note on Thursday, February 20th. Finally, HC Wainwright restated a "buy" rating and issued a $221.00 target price on shares of Krystal Biotech in a research report on Friday, February 28th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Krystal Biotech has an average rating of "Buy" and an average target price of $220.00.

Insider Transactions at Krystal Biotech

In other news, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the transaction, the chief accounting officer now directly owns 12,604 shares in the company, valued at $2,208,472.88. This trade represents a 5.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the transaction, the insider now directly owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. The trade was a 1.68 % decrease in their position. The disclosure for this sale can be found here. 13.70% of the stock is currently owned by corporate insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).